格隆汇10月30日｜平安证券研报指出，爱尔眼科单Q3归母净利润10.64亿元（yoy-24.12%），25年1-9月 归母净利润31.15亿元（yoy-9.76%）。利润率下降，费用持续管控。公司"1+8+N"战略取得实质进展， 纵向分级连锁网络体系不断完善，横向同城分级诊疗网络持续推进，区域内资源配置效率及共享程度进 一步提高。另一方面，公司国际化战略的持续推进，有助于深度融合国际先进医疗服务理念和最前沿技 术体系，嫁接先进的服务模式、医疗技术和管理经验，帮助公司更好地发展国内的医疗服务，逐步搭建 世界级科研、人才、技术创新平台。宏观政策加大对经济刺激力度，未来经济有望修复，消费医疗赛道 业绩有望修复，公司为赛道头部公司经营具备韧性，维持"推荐"评级。 ...

公 司 报 告 医药 2025年10月30日 爱尔眼科(300015.SZ) 业绩短期承压，"1+8+N"战略持续推进 推荐 ( 维持) 股价:12.17元 | 行业 | 医药 | | --- | --- | | 公司网址 | www.aierchina.com | | 大股东/持股 | 爱尔医疗投资集团有限公司/34.34% | | 实际控制人 | 陈邦 | | 总股本(百万股) | 9,325 | | 流通A股(百万股) | 7,931 | | 流通B/H股(百万股) | | | 总市值(亿元) | 1,135 | | 流通A股市值(亿元) | 965 | | 每股净资产(元) | 2.41 | | 资产负债率(%) | 33.5 | 行情走势图 主要数据 倪亦道 投资咨询资格编号 S1060518070001 事项： 公司发布25Q3季报，单Q3收入59.77亿元（yoy+3.83%），归母净利润10.64 亿元（yoy-24.12%），扣非归母净利润10.80亿元（yoy-18.73%）。25年1-9 月收入174.84亿元（yoy+7.25%），归母净利润31.15亿元（yoy-9.76%）， 扣非 ...

Core Viewpoint - Huawei's Pura 80 series represents a significant advancement in imaging technology while maintaining the same pricing strategy as its predecessor, Pura 70, aiming to compete directly with Apple in the high-end smartphone market [2][3][4]. Group 1: Product Launch and Pricing Strategy - Huawei officially launched the Pura 80 series on June 11, featuring three models: Pura 80 Pro starting at 6499 yuan, Pura 80 Pro+ at 7999 yuan, and Pura 80 Ultra at 9999 yuan [2]. - The Pura 80 series continues the "add more without raising prices" strategy, which reflects Huawei's confidence in the product's capabilities and aims to enhance channel performance [3][10]. Group 2: Technological Innovations - The Pura 80 series features significant advancements in imaging technology, including a one-inch main camera sensor and the introduction of the "one lens dual focus" periscope telephoto lens in the Ultra model, which is a first in the industry [7][8]. - Huawei has invested heavily in R&D, with a total of 12.49 billion yuan over the past decade, and 1.797 billion yuan in 2024 alone, accounting for 20.8% of its annual revenue [6]. Group 3: Market Position and Sales Strategy - The Pura 80 series aims to leverage the high school examination season to boost sales, with promotional activities targeting students and their parents [11][12]. - Huawei's market share in the high-end segment (over $600) reached 38% in Q1 2025, showing a 69% year-on-year growth, while Apple’s market share declined by 9% to 43% [17]. Group 4: Software Integration and Ecosystem Development - The Pura 80 series is equipped with the HarmonyOS 5.1, enhancing user experience and integrating various smart devices within Huawei's ecosystem [4][15]. - The new HarmonyOS features, including an upgraded AI assistant, aim to improve user interaction and expand the ecosystem's capabilities [16].

Core Viewpoint - The company aims to focus on organic growth while completing its mission of external mergers and acquisitions, with a strategic emphasis on the "1+8+N" model and the integration of artificial intelligence in ophthalmology services [2][3]. Financial Performance - In 2024, the company reported a revenue of 20.983 billion yuan, a year-on-year increase of 3.02%, and a net profit exceeding 3.5 billion yuan, growing by 5.87% [2]. - In Q1 2025, the company returned to high growth, achieving a revenue of 6.026 billion yuan, up 15.97%, and a net profit of 1.05 billion yuan, increasing by 16.71% [2]. Strategic Development - The "1+8+N" strategy has been fully implemented, with significant progress in establishing regional ophthalmology centers across China, including flagship hospitals in Shanghai and Nanning [3]. - The company has expanded its operational footprint to 352 ophthalmology hospitals and 229 outpatient departments, enhancing its chain operation advantages [3]. Digital Transformation - The company has made notable advancements in digital ophthalmology and AI applications, collaborating with the Chinese Academy of Sciences to explore the establishment of "Aier AI Eye Hospital" [4]. - The company launched its self-developed ophthalmology vertical model AierGPT and the digital persona "Eyecho," enhancing service efficiency and patient experience [4]. Social Responsibility - The company integrates public welfare into its development strategy, conducting vision health screenings and education in schools and rural areas, and has donated 217 million yuan in 2024 [5]. - The company has established a stable cash dividend system, with a total cash dividend of approximately 1.487 billion yuan for 2024, maintaining a consistent dividend payout for 15 years [5].

Core Viewpoint - The company reported a revenue of 20.98 billion yuan for 2024, with a year-on-year growth of 3.0%, and net profits meeting market expectations. The first quarter of 2025 showed a revenue of 6.03 billion yuan, a year-on-year increase of 16.0%, exceeding market expectations, primarily due to the recovery in consumer business [1]. Group 1: Business Performance - In 2024, the consumer business faced pressure, with refractive and optical revenues growing by 2.3% and 6.4% year-on-year, respectively. However, in Q1 2025, both segments are expected to outperform the overall company revenue growth due to the elimination of price base pressure and the application of new technologies [2]. - The serious medical segment maintained stable growth in 2024, with cataract, anterior segment, and posterior segment revenues increasing by 4.9%, 5.9%, and 8.2% year-on-year, respectively. The company anticipates continued stable performance in Q1 2025 [2]. Group 2: Expansion and Service Improvement - By the end of 2024, the company operated 581 domestic medical institutions and 163 overseas institutions, having acquired nearly 90 domestic medical institutions and the Optimax Group to enter the UK ophthalmology market. This expansion is expected to enhance market positioning and achieve economies of scale [3]. - The company is optimizing service models by extending outpatient hours and building smart hospital platforms to meet diverse patient needs, achieving a patient satisfaction rate close to 99.0% in 2024 [3]. Group 3: Financial Metrics - In 2024, the company reported a gross margin of 48.1%, a sales expense ratio of 10.3%, and a management expense ratio of 14.2%. The net profit margin for the parent company was 16.9% [4]. - In Q1 2025, the company achieved a gross margin of 48.0%, with a reduction in sales and management expense ratios to 9.0% and 12.6%, respectively. The net profit margin for the parent company increased to 17.6% year-on-year [4]. Group 4: Profit Forecast and Valuation - The company adjusted its net profit forecast for 2025-2026 down by 7.73% and 7.94% to 4.09 billion yuan and 4.699 billion yuan, respectively. The current stock price corresponds to a P/E ratio of 29.9x for 2025 and 26.0x for 2026 [5]. - The target price is maintained at 16.0 yuan, corresponding to a P/E ratio of 36.5x for 2025 and 31.8x for 2026, indicating a potential upside of 22.0% from the current stock price [5].